Latest Proteasome inhibitor Stories
Maximum tolerated dose (MTD) identified and expansion cohort open to enrollment; Minimal Response (MR) or better has been observed in 25% of 8 patients treated to date at the MTD or higher
BURLINGAME, Calif., Sept.
TG02 synergizes with carfilzomib in multiple myeloma models; data to be presented at ASH 2013 Annual Meeting. San Diego (PRWEB) December 03, 2013 Tragara
Researchers have discovered why multiple myeloma, a difficult to cure cancer of the bone marrow, frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years.
A new study from SUNY Downstate Medical Center in Brooklyn, New York, shows that MAL3-101, a recently developed inhibitor of the heat shock protein 70 (Hsp70), appears to have potent anti-tumor effects on multiple myeloma, a bone marrow cancer.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.